Quarterly report pursuant to Section 13 or 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

v3.2.0.727
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Jun. 30, 2015
Jun. 30, 2014
Operating expenses:        
Research and development $ 604,108 $ 92,435 $ 925,547 $ 310,303
General and administrative 939,487 510,244 1,722,333 1,166,460
Total operating expenses 1,543,595 602,679 2,647,880 1,476,763
Other income (expense), net:        
Research and development tax credit 0 22,575 0 25,515
Interest income 2,242 324 2,406 631
Interest expense 0 (62,154) (1,920,146) (94,209)
Change in warrant liability 0 (5,000) 223,172 (5,000)
Other income (expense), net 0 0 9 0
Total other income (expense), net 2,242 (44,255) (1,694,559) (73,063)
Net Loss (1,541,353) (646,934) (4,342,439) (1,549,826)
Deemed dividend on preferred stock 0 0 (8,222,008) 0
Net income attributable to non-controlling interests 0 (58,314) (5,177) (117,262)
Net loss attributable to Eyegate Pharmaceuticals, Inc. common stockholders $ (1,541,353) $ (705,248) $ (12,569,624) $ (1,667,088)
Net loss per common share - basic and diluted $ (0.24) $ (3.82) $ (2.57) $ (9.04)
Weighted average shares outstanding - basic and diluted 6,363,027 184,474 4,898,405 184,474
Net loss $ (1,541,353) $ (646,934) $ (4,342,439) $ (1,549,826)
Other comprehensive income (loss):        
Foreign currency translation adjustments 29,988 (14,071) 81,313 (5,077)
Comprehensive loss (1,511,365) (661,005) (4,261,126) (1,554,903)
Less:        
Net income attributable to non-controlling interests 0 (58,314) (5,177) (117,262)
Other comprehensive (income) loss attributable to non-controlling interests 0 (24,307) 32,967 (31,126)
Comprehensive (income) loss attributable to non-controlling interests 0 (82,621) 27,790 (148,388)
Comprehensive loss attributable to Eyegate Pharmaceuticals, Inc. stockholders $ (1,511,365) $ (743,626) $ (4,233,336) $ (1,703,291)